Table 2.
Treatment Patterns for Chronic Symptomatic FBDs in the United States
| Disorder, n (95% CI) | Weighted percentage of visits (95% CI) |
|||
|---|---|---|---|---|
| Medication only | Nonpharmacologic therapya only | Combined medication and nonpharmacologic therapy | No treatment | |
| All chronic functional bowel disorders 36,694,000 (31,233,000–42,156,000) |
39.3 (35.6–46.5) | 9.3 (7.0–12.4) | 10.5 (7.9–13.7) | 40.9 (35.6–46.5) |
| IBS or chronic abdominal pain 24,381,000 (20,304,000–28,458,000) |
36.7 (31.5–42.1) | 9.7 (7.1–13.3) | 9.2 (6.1–13.5) | 44.4 (37.8–51.3) |
| Chronic constipation 8,820,000 (6,807,000–10,832,000) |
47.4 (39.2–55.8) | b | 12.8 (8.2–19.4) | 29.4 (22.0–38.1) |
| Chronic diarrhea 6,165,000 (4,793,000–7,538,000) |
44.1 (33.4–55.3) | b | 12.1 (6.5–21.2) | 37.5 (27.8–48.3) |
a
Nonpharmacologic therapy includes dietary/nutrition counseling, exercise (including physical therapy) or weight reduction counseling, stress reduction and mental health counseling (including psychotherapy), and complementary and alternative medicine.
b
Weighted estimate suppressed because of <30 unweighted observations or relative standard error of >30% (unreliable estimate).